Science Spotlight: Advances in RSV and hMVP vaccines 

A pair of studies by independent groups revealed advances in respiratory syncytial virus (RSV) and human metapneumovirus (hMVP) vaccines. 

In the first study, published in Nature Microbiology, Johnson & Johnson (NYSE:JNJ) developed an RSV vaccine that prevents lower respiratory tract infections similar to current RSV vaccines, but without inducing potentially problematic antibodies against a vaccine design component...